Approval · Notice of Compliance 30011 · 2023
AVALIDE: Notice of Compliance 30011
Issued January 30, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30011
- Date
- January 30, 2023
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVALIDE | Not yet assigned | — |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- IRBESARTAN 150 MG per TAB
- IRBESARTAN 300 MG per TAB